Tanvex BioPharma Reports the US FDA’s Approval of Nypozi (Biosimilar, Neupogen)
Shots:
- The US FDA has granted BLA approval of Nypozi (TX01), biosimilar version of Amgen’s Neupogen
- Nypozi (TX01) is intended to reduce the incidence of infection among patients having non-myeloid malignancies undergoing chemotherapy that may reduce neutrophil count
- The company’s Nypozi was introduced across Canada in Jan 2024
Ref: Tanvex | Image: Tanvex
Related News:- Coherus Reports the Divestment of Yusimry (Biosimilar, Humira) to Hong Kong King-Friend Industry
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies. He can be contacted at connect@pharmashots.com
